ISQCH researchers develop a biomolecule that identifies and treats lung tumors
15 July 2020
Researchers find three types of immune response in severe Covid-19 patients
16 July 2020
Studies show that the therapy triggers an immune response with mild side effects, such as fatigue, chills, headache, muscle pain, and pain at the injection site.
The coronavirus vaccine developed by the biotechnology company Moderna has generated "rapid and strong" immune responses in all the volunteers who received it in phase one of the research and could be ready by 2021.
The first results of Moderna's research were published this Tuesday in the 'New England Journal of Medicine' and, specifically, they show that the vaccine triggers an immune response with mild side effects, such as fatigue, chills, headache, pain muscle and pain at the injection site.
The vaccine, developed together with the US National Institutes of Health, is expected to begin phase three of the trial, the final stage of the research, on July 27 with 30.000 volunteers.
Thus, as Moderna stated in a statement, "the company is on track to be able to deliver approximately 500 million doses per year and possibly up to one billion doses per year starting in 2021."
According to the World Health Organization (WHO), around 300 coronavirus vaccines are currently in the trial phase.
